Bitcoin

The article highlights targeted protein degraders as the next frontier after tyrosine kinase inhibitors, a space where traditional pharma R&D costs are exploding. This creates a natural opening for DeSci protocols (e.g., VitaDAO, Molecule) to fund and IP-tokenize early-stage research. In a market where BTC dominance is high and altcoins are underperforming, narrative-driven sectors like DeSci are exactly the kind of niche that can attract speculative capital once the next altcoin rotation begins.

A Nature article discusses how targeted protein degraders could reshape therapeutic options in cancer treatment, building on tyrosine kinase inhibitors.

Nature Flags Targeted Protein Degraders as Next Cancer Frontier, and DeSci Is Listening

Targeted protein degraders will create a new class of on-chain IP-NFTs and decentralized biotech DAOs, turning cancer research into a crypto-native asset class.